The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs

Drug Metabolism and Disposition

Volumn 28, Issue 10, 2000, Pages 1244-1254

  Halpin, R A ^a   Geer, L A ^a   Zhang, K E ^a   Marks, T M ^a   Dean, D C ^a   Allen, N ^a   Jones, A ^a   Melillo, D ^a   Doss, G ^a   Vyas, K P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROROFECOXIB; 4' HYDROXYROFECOXIB SULFATE; 5 HYDROXYROFECOXIB; 5 HYDROXYROFECOXIB O BETA DEXTRO GLUCURONIDE; BETA GLUCURONIDASE; CARBON 14; CYCLOOXYGENASE 2 INHIBITOR; DRUG METABOLITE; ROFECOXIB; ROFECOXIB 3',4' DIHYDRODIOL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE; BLADDER; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FOOD DRUG INTERACTION; LIVER; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROSTATE; RAT; SKIN; STEADY STATE; STEREOCHEMISTRY; URINE;

ABSORPTION; ANIMAL; AREA UNDER CURVE; BILE; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE INHIBITORS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; KINETICS; LACTONES; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 0033815066     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Chemical structure and pharmacological activity of some derivatives of digitoxigenin and digoxigenin
2. Tissue weights of the rat. I. Normal values determined by dissection and chemical methods
3. Rofecoxib [Vioxx, MK-0966; (4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
4. COX-II inhibitors: A new generation of safer NSAIDs?
5. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
6. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes
7. Cyclo-oxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs
8. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme
9. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice
10. The discovery of rofecoxib [MK-966, VIOXX, 4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
11. Formation of [20R]-dihydrodigoxin from digoxin in humans
12. Hematology and clinical biochemistry
13. Acetylation of prostaglandin synthase by aspirin
14. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans
15. Laser desorption/Fourier transform ion cyclotron resonance mass spectrometry: Digoxin, digitoxin, and their reduced and sugar-hydrolyzed metabolites
16. Prostaglandin endoperoxide synthases-1 and -2
17. Prostaglandin endoperoxide synthase: Structure and catalysis
18. Stereoselectire metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes
19. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
20. Overview-mechanisms of action of anti-inflammatory drugs
21. Identification by gas chromatography-mass spectroscopy of dihydrodigoxin: A metabolite of digoxin in man
22. The determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection